Publications by authors named "A Sekulic"

Acute kidney injury (AKI) incidence after neurosurgical operations has been reported as 10-14%. The literature regarding the incidence of nosocomial acute kidney disease (AKD) following neurosurgery is scarce. This retrospective, single-center, observational study aimed to assess the impact of different anaesthetics on development of postoperative AKI and persistent AKD in neurosurgical patients.

View Article and Find Full Text PDF

Objective: To execute a large-scale, decentralized, clinical-grade whole exome sequencing study, coined Tapestry, for clinical practice, research discovery, and genomic education.

Patients And Methods: Between July 1, 2020, and May 31, 2024, we invited 1,287,608 adult Mayo Clinic patients to participate in Tapestry. Of those contacted, 114,673 patients were consented and 98,222 (65.

View Article and Find Full Text PDF

: Pectus excavatum (PEx) is considered, at least partially, a familial disorder. A variety of inheritance patterns, associations with genetic syndromes, and pathogenic variants have been reported. However, the etiology of this condition is still not completely understood, and no known genes have been identified as definitive contributors.

View Article and Find Full Text PDF
Article Synopsis
  • Drug repurposing offers a cost-effective strategy for developing therapies for rare diseases, which often face challenges in traditional drug development.
  • This study used a new drug identification and repurposing pipeline to discover molecular drivers and potential therapies for psoriasis, leading to the identification of both known and novel disease mechanisms.
  • The approach was further applied to necrobiosis lipoidica, revealing important disease drivers and potential treatments, demonstrating a high success rate in matching drugs to identified molecular targets.
View Article and Find Full Text PDF
Article Synopsis
  • The study assessed health-related quality of life (HRQoL) in 84 patients with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab.
  • Patients received cemiplimab every 3 weeks for up to 9 cycles, and HRQoL was evaluated using the QLQ-C30 and Skindex-16 questionnaires at various points.
  • Results showed that 62-90% of patients experienced improvement or maintenance in HRQoL, except for fatigue, which remained a concern throughout the treatment.
View Article and Find Full Text PDF